LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosures
On December 5, 2016, Lipocine Inc. issued a press release
announcing the initiation of a dosing validation study for LPCN
1021. The press release is filed as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following exhibits are filed with this report:
| Exhibit No. | Description |
| 99.1 |
Press Release Announcing the Initiation of the Dosing Validation Study for LPCN 1021 |
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs. LIPOCINE INC. (NASDAQ:LPCN) Recent Trading Information
LIPOCINE INC. (NASDAQ:LPCN) closed its last trading session up +0.20 at 3.47 with 123,639 shares trading hands.
